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A MODEL OF BACTERIAL SUPERINFECTION IN AN
INFLUENZA-INFECTED HOST
Sherry B. Linn, M.S.
University of Pittsburgh, 2011
Bacterial pneumonia is a common complication of influenza A infection. We create an ODE
model of bacterial infection with state variables representing the respective levels of bacteria,
impaired and active neutrophils, and the anti-inflammatory molecule interleukin 10 (IL-10).
After fitting the parameters, we obtain a model that demonstrates bistability between states
of health and chronic bacterial infection. The fitted model also closely reproduces IL-10 data
obtained from a model of mice inoculated with a strain of influenza A virus. Additionally,
we develop a different model similar to the first but with stochastic intake of bacteria to
represent the inhalation of small amounts of bacteria into the lungs many times daily. We
find a set of parameters for which the second model produces a fit to the IAV IL-10 data.
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1.0 INTRODUCTION
The term superinfection refers to the situation in which a pathogen infects a host while the
host is already battling an infection. A well-known example is the occurrence of bacterial
pneumonia shortly after influenza infection. This is the main cause of death from seasonal
influenza, which claims 35,000 lives annually in the United States of America. There are
many possible causes of superinfections. One theory is that the primary infection elicits an
immune response, creating a window of time during which the immune system is not at the
resting equilibrium state of health and is susceptible to infection by another pathogen. This
window occurs due to neutrophil paralysis, the prevention of neutrophil migration to the site
of bacterial infection by a canonical anti-inflammatory molecule, IL-10.
It is well documented that the seasonal flu has a higher mortality rate among the elderly
population (aged 65 year or older) than it does among younger individuals. In a study by
Toapanta et al. that sought to better understand this phenomenon, aged and adult mice
were infected with a strain of IAV (A/Puerto Rico/8/34) and then monitored for differences
in immune dynamics [11]. In both aged and adult mice; weight loss, mortality, and virus titer
were monitored. In addition, cells of the innate and adaptive immune response, cytokines
and chemokines produced by immune cells were all analyzed and counted.
Although unmentioned in their manuscript, Toapanta et al. measured levels of IL-10
(pg/mL) for the experiment discussed in [11]. Figure 1 shows levels of IL-10 taken for a
sublethal case in IAV-infected adult mice up to 19 days post-infection. The figure also shows
virus titer data from the mice during the same span of days. The first and larger hump in
the IL-10 data is due to the host immune response to the IAV infection. As described in
Section 2.2.3, the host immune response to pathogenic invasion is a pro-inflammatory wave
shortly followed by an anti-inflammatory wave, which we observe in the first peak in the
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IL-10 data. Note the increase in IL-10 on Day 11 despite the absence of virus after Day 9.
We hypothesize that this unexpected hump in IL-10 levels is due to an unintended secondary
bacterial infection facilitated by the inoculation of the mice with IAV.
Specifically, we believe that the facilitation of the bacterial infection can be explained as
a result of the immune response to the IAV infection. The first peak in IL-10 data marks the
anti-inflammatory wave initiated by the IAV infection, during which neutrophil paralysis is
known to occur. We posit that the temporary paralysis of neutrophils allows the bacteria to
reproduce and spread; the neutrophils are not at the site of infection to attack the bacteria
and to signal other pro-inflammatory effectors to the infection site.
Section 2 provides an introduction to the topics of influenza infection, pneumonia, super-
infection, and immune response. It also gives a brief review of literature on research related
to viral-bacterial superinfections and IAV-bacterial pneumonia superinfections.
In Section 3, we analyze the dynamics of a two-equation ordinary differential equation
(ODE) model of interactions between bacteria and activated neutrophils. We then develop a
four-equation model based on the two-equation model, this time also including interactions
involving IL-10 and paralyzed neutrophils. We take the IL-10 output from the IAV infection
to be the difference between the linear interpolation of the first seven data points and the
IL-10 steady state level. The IL-10 output from the bacterial infection is determined by the
model dynamics. We then find a set of parameters for which the total IL-10 matches the
linear interpolation of all given IL-10 data points.
In Section 4, we develop a model similar to that in the previous section, using stochastic
inhalation of bacteria many times per day, instead of using a constant rate of bacteria
inhalation, into the lower respiratory tract. Because the IL-10 data comes from several mice,
we find the average total IL-10 produced by the system, and compare it to the given IL-10
mouse data. We find a set of parameter values for which the system’s average total IL-10 is
a close match to the linear interpolation of the ten given IL-10 data points.
In Section 5, we conclude by discussing possible extensions of research involving the
model with stochastic bacteria inhalation.
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Figure 1: The 10 data points of IL-10 levels (blue) and viral titer levels (green) in IAV-
infected mice collected by Toapanta et al. over the course of 19 days post infection. The
lines between data points indicate piecewise linear interpolation based on the given data.
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2.0 BACKGROUND AND MOTIVATION
2.1 IAV AND BACTERIAL PNEUMONIA
The influenza virus is known globally as a public health concern and a hindrance to society,
responsible for high levels of work absenteeism, productivity losses, and the overwhelming
of medical facilities caused during peak influenza illness periods. The symptoms of influenza
infection include fever, chills, headache, muscle pain, fatigue, and nasal congestion. Influenza
can be fatal when it leads to lethal complications. Annually, seasonal influenza epidemics
result in 250,000-500,000 deaths and 3-5 million cases of severe illness worldwide [14]. These
figures do not include pandemics; the 1918, 1957, and 1968 influenza pandemics had esti-
mated death tolls of 40-50 million, 2 million, and 1 million people, respectively [15]. There
are three types of influenza virus: influenza A, B, and C. Of these three types, influenza A
virus (IAV) is the most virulent. To this point, the 1918, 1957, 1968, and 2009 pandemic
strains of influenza were of type A, making IAV a topic of research across many disciplines,
including immunology, microbiology, and mathematical biology.
Pneumonia is a respiratory condition often characterized by the filling of alveoli with
inflammatory fluid interfering with gas exchange. This fluid accumulation is the direct effect
of vasoactive agents produced by inflammatory cells, such as neutrophils, in their efforts to
contain and eradicate invading bacteria. In severe cases of pneumonia, gas exchange is so
impaired that animals die and humans require mechanical ventilatory support in intensive
care units and incur substantial mortality, as well. Pulmonary inflammation associated with
pneumonia can also lead to pleural effusion, empyema (infected effusion), lung abscesses,
and acute lung injury (ALI). ALI is a condition in which pulmonary inflammation persists
irrespective of the presence of bacteria. Pneumonia is a major cause of death in the elderly,
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infants and young children, and individuals with chronic illness. Streptococcus pneumoniae
is the bacteria most commonly associated with bacterial pneumonia infections [2], [5], [8].
Staphylococcus aureus and Haemophilus influenzae are other bacteria known to cause pneu-
monia.
There is much evidence of IAV-bacterial pneumonia superinfections. A recent study by
Morens et al. of autopsy data and tissue samples from 58 victims of the 1918 IAV pandemic
found common respiratory-tract bacteria and other histological indicators of acute bacterial
pneumonia infection in most of the samples. This discovery led the authors to conclude
that the majority of 1918 IAV pandemic deaths were directly caused by secondary bacterial
pneumonia as opposed to being caused by the IAV infection itself [8]. The same study
concluded similar results with respect to the 1957 and 1968 IAV pandemics.
There is also evidence that correlates bacterial pneumonia with severe illness in patients
infected with 2009 pandemic H1N1 (H1N1 pdm). The Center for Disease Control (CDC)
received lung tissue samples from 77 American victims of H1N1 pdm, collected from May
1, 2009 to August 20, 2009 [13]. Analysis of these samples exhibited evidence of concurrent
bacterial infection in 22 of the victims. S. pneumoniae was the most prevalent bacteria in
this study, found in 10 of the 22 victims showing concurrent bacterial infection. Palacios, et
al. conducted a similar study of Argentineans infected with H1N1 pdm [9]. They studied
199 cases of patients diagnosed with H1N1 pdm infection; 160 cases were diagnosed as mild
and 39 as severe. S. pneumoniae was found in the patient’s respiratory tract in 62 of the
H1N1 pdm cases, 22 of these cases involving severe IAV infection and the remaining 40 being
mild. From this data, the study concluded that the presence of S. pneumoniae in H1N1-pdm
infected patients is a significant indicator of severe illness.
The given examples suggest a correlation in severity of illness in IAV-infected patients
and secondary bacterial infection, i.e. that the lethality of IAV is increased in cases in which
bacterial pneumonia is contracted. Experiments by McCullers et al. further support the ex-
istence of such a relationship between IAV and bacterial pneumonia [7]. To test the efficacy
of antiviral treatments in cases of bacterial pneumonia following IAV infection, McCullers et
al. inoculated four groups of six mice with S. pneumoniae. Three of these groups were also
inoculated with the same strain of IAV seven days prior to inoculation with S. pneumoniae.
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These three groups were each given one of three antiviral treatments: oseltamivir, riman-
tidine, or a placebo. Oseltamivir inhibits neuraminidase (NA), while rimantidine inhibits
the M2 proton channel protein (M2). If the mice exhibited signs of pneumonia, they were
treated with the antibiotic ampicillin. All mice that were inoculated with only S. pneumo-
niae survived and five of the six mice in the oseltamivir group survived, while none of the
mice in the rimantidine group survived and none of the mice in the placebo group survived.
There is much evidence that influenza increases adherence of bacteria to epithelial cells. The
authors found that inhibition of NA reduces the adherence of S. pneumoniae to alveolar
basal epithelial cells, whereas inhibition of M2 does not. This agrees with the results that
mice coinfected with IAV and S. pneumoniae that were treated with oseltamivir and ampi-
cillin had a greater survival rate compared to those treated with rimantidine and ampicillin.
The results of this experiment suggest that S. pneumoniae is not fatal by itself, but that
infection with IAV followed by infection with S. pneumoniae can be fatal, supporting that
influenza affects the pathogenesis of bacterial pneumonia in such a way that S. pneumoniae
is able to overwhelm the host before specific immune responses can develop.
In another experiment by McCullers et al., 30 mice were infected intranasally with IAV
and then inoculated with S. pneumoniae seven days later [7]. 22 of the mice were treated
with oseltamivir and ampicillin. All mice given both the anti-viral and antibiotic treatments
survived. Seven of these 22 mice developed pneumonia and had visually cleared the pneu-
monia by the eighth day post S. pneumoniae infection. The other eight of the 30 mice
were treated with ampicillin alone. All eight of these mice developed pneumonia and died,
even though six of these eight mice had visibly cleared the pneumonia before death. On the
basis of this experiment, the authors hypothesized that treatment with oseltamivir delays
the onset and slows the progression of bacterial pneumonia by lessening the severity and
duration of IAV. This in turn could alter the pathogenesis of bacterial pneumonia so that
the clearance of S. pneumoniae is enough to bring the mice back to health.
The findings of these experiments by McCullers et al. show that bacterial pneumonia is
more likely to develop in an S. pneumoniae-infected host recovering from an IAV infection
than it is to develop in a host battling a S. pneumoniae without a proceeding IAV infection.
This, in addition to the correlation between severity in H1N1 pdm-infected patients and
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secondary S. pneumoniae infection found in the study by Palacios et al., demonstrates that
IAV and S. pneumoniae have a synergistic relationship that leads to an outcome worse than
the outcome of the host had it been infected with only IAV or only S. pneumoniae.
According to Bakaletz, the presence of IAV is often necessary for bacterial infection to
establish itself in the lower respiratory tract [2]. The well-documented prevalence of bacterial
pneumonia following IAV infection and the increased mortality that secondary bacterial
pneumonia can lead to in IAV-infected patients has led to research as to the possible causes
of this phenomenon.
2.2 VIRAL POTENTIATION OF BACTERIAL INFECTION
2.2.1 Examples
It is important to note that the permissive relationship between IAV and bacterial pneu-
monia is not the only documented example of viral infections amplifying the potency of
bacterial infections when the two infections occur within close chronological proximity to
one another. Bakaletz points out that sinusitis is often observed after rhinovirus, influenza,
adenovirus, or parainfluenza virus infections [2]. Also, in an experiment by Giebink in which
chinchillas were either infected with IAV alone, S. pneumoniae alone, or both IAV and S.
pneumoniae, IAV was found to potentiate otitis media infection [2]. Suzuki and Bakaletz
observed through experiment with a similar model that adenovirus potentiates Haemophilus
influenzae; whether the subjects were inoculated with adenovirus before or after infection
with H. influenzae, both the severity and incidence of otitis media increased [2]. In the
1940s, many studies were conducted on animal models in which infection with influenza
virus followed by infections with any of several pneumopathic bacteria resulted in a higher
occurrence of disease, shortened time to death, or higher death rate [8].
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2.2.2 Causes
Much research has been conducted in order to unearth the causes of and mechanisms re-
sponsible for viral potentiation of bacterial infection. Goldstein et al. looked to formulate
a correlation between bacterial infections and viral infections that precede them through
an experiment in which some mice were immunized against Mengo-37A, a weak strain of
encephalomyocarditis (ECM) virus, while the remaining mice in the experiment were not
[4]. All mice were then either inoculated with Columbia-SK, which is a virulent strain of
ECM virus, Mengo-37A, or a placebo. Finally, all mice were inoculated with Staphylococcus
aureus. The immunized mice that were infected with either strain of the ECM virus expe-
rienced respiration and pulmonary bactericidal activity similar to that of the control mice.
Non-immunized mice that were infected with Columbia-SK were observed to have bacterici-
dal dysfunction worse than that observed in non-immunized mice infected with Mengo-37A.
This experiment connects virulence of the preceding virus with an inability to clear a sec-
ondary bacterial infection. It also provides an example of how the physiological effects of a
viral infection can yield changes that potentiate a bacterial infection.
There are other possible reasons as to why viral-bacterial superinfections tend to be more
pathogenic than the bacterial infection would be without the preceding viral infection. For
example, IAV and other viral infections in the respiratory tract result in damage to respi-
ratory epithelia, which exposes the basement membrane as well as surfaces of regenerating
cells. These exposed surfaces are possible binding sites for bacteria, allowing the bacteria
to populate in the respiratory tract where they would normally not be able to do so. Viral
infection of epithelial cells that have not already been destroyed can also lead to the creation
of potential bacterial binding sites, in this case on the infected host cell [2]. For example, the
influenza virus has been found to increase the adherence of bacteria to epithelium in vitro,
in animal models, and in humans [7]. Destruction of respiratory epithelium also negatively
impacts the ability of cilia to move particles, bacteria, and fluid out of the lower respiratory
tract [2]. The lower respiratory tract is thought to be sterile of bacteria [2]. The mucociliary
escalator is the primary defense against bacteria that contaminate the upper respiratory tract
and is what keeps the lower respiratory tract virtually free of bacteria; however, damage to
8
the cilia allows bacteria the opportunity to populate the lower respiratory tract.
McAuley et al. focused on PB1-F2, a proapoptotic IAV protein found in the pandemic
1918 strain, as a possible factor in the lethality of the 1918 flu pandemic via secondary
bacterial pneumonia [6]. They conducted an experiment involving a wild-type strain (WT)
and an isogenic strain (mut) of the mouse-adapted influenza A/Puerto Rico/8/34 (PR8)
strain. The mut PR8 was engineered so as to significantly reduce the expression of PB1-
F2. Two groups of six mice were infected with either the WT or mut viruses and then
inoculated with S. pneumoniae seven days later. The group of mice infected with the WT
virus experienced greater weight loss, incidence of bacterial pneumonia, and mortality than
the group of mice infected with the mut virus. The control mice, which were not inoculated
with S. pneumonia, survived regardless of whether they were infected with the WT virus
or the mut virus. The authors concluded that PB1-F2 is pro-inflammatory to the host,
can enhance the virulence of the strain of IAV that contains it, and facilitates secondary
bacterial pneumonia. They suggested that the apoptosis of host cells caused by PB1-F2 sets
off a positive feedback loop of inflammatory cytokines, which is amplified by the presence of
bacterial pneumonia. This, in turn, enhances the inflammatory response to the IAV in the
lungs.
From the account of immunopathological death described by McAuley et al., it is clear
that the immune response induced by viral infection is important to consider when inves-
tigating possible reasons for the synergistic relationship of viral-bacterial superinfections.
In the second experiment by McCullers et al. described above, six out of the eight mice
treated with only antibiotic were able to visibly clear the S. pneumoniae from their lungs
but nonetheless did not survive the IAV-S. pneumoniae coinfection. This also suggests an
immunopathological death – an inability for the host to return to health despite the absence
of the bacteria that initially caused the pneumonia.
2.2.3 The Immune Response to Infection and Neutrophil Paralysis
The host immune response to acute stress, such as IAV infection, begins with a wave of pro-
inflammatory cytokines including interleukin-1 (IL-1), interleukin-8 (IL-8), interferon gamma
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(INF-γ), and interferon alpha (INF-α). These cytokines mobilize neutrophils and other
immune effectors so as to contain and clear the pathogen. Almost immediately following is a
wave of anti-inflammatory cytokines, which inhibit pro-inflammatory cytokines and initiate
the healing response. The repression of pro-inflammatory mediators creates a window of
opportunity for secondary infections to thrive [1]. The suppression of neutrophil migration
to the site of pathogen infection is another possible manner in which viruses can potentiate
bacterial infections [2].
Neutrophils are the first line of defense against infection, migrating through blood vessels
by chemotaxis in response to the secretion of IL-1, IL-8, INF-α, and INF-γ. The impairment
of neutrophil migration to an infection site is known as neutrophil paralysis and is related to
the depletion of appropriate cell surface receptors to IL-8 on neutrophils. This phenomenon
is a key feature in sepsis, a condition in which a bacterial infection may not be cleared,
while the entire system is overwhelmed with inflammation. Interleukin-10 (IL-10) is an anti-
inflammatory cytokine that is a major regulator of inflammation and has been found to
inhibit cytokine expression, in the lung in particular [10]. In the absence of the secretion of
cytokines at the site of infection, neutrophils cannot migrate to the site of infection. IL-10
is also inhibits the ability for neutrophils to phagocytose the bacteria.
The effects of neutrophil impairment and overexpression of IL-10 were studied in an ex-
periment by Sun et al. [10]. Mice were genetically altered with a gene that overexpresses
IL-10 in the lungs only when induced with tetracycline. These mice (IL-10 OE) and control
mice (WT) were inoculated with Pseudomonas aeruginosa. The IL-10 OE mice experienced
neutrophil paralysis and increased bacteria counts in comparison to the WT mice. In a
different experiment, neutrophil depletion was induced in IL-10 OE mice and in WT mice,
resulting in impaired bacterial clearance in both types of mice [10]. The authors concluded
that the neutrophil paralysis associated with IL-10 leads to increased bacterial counts, in-
creased inflammation in the lungs, and a higher incidence of mortality.
From the above experiment by Sun et al., it is clear that neutrophil paralysis has detri-
mental effects in the face of bacterial infection. Neutrophil paralysis has also been observed
in patients with leukemia, diabetes, and AIDS, all of which are diseases associated with a
high susceptibility to secondary bacterial infection [1].
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3.0 MODEL 1: DETERMINISTIC INHALATION OF BACTERIA
In order to test the plausibility of the hypothesis that the second wave of IL-10 observed in the
IAV mouse data collected by Toapanta et al. is caused by a secondary bacterial infection,
we develop an ODE model containing state variables representative of the quantities of
paralyzed neutrophils, NP , activated neutrophils, NA, bacteria, B, and IL-10 produced in
response to the bacterial infection, I. We will begin by developing a two-equation ODE
model representative of the interaction between activated neutrophils and bacteria.
3.1 THE B-NA SUBSYSTEM
When developing the B-NA subsystem, we take into account the interactions between bac-
teria and activated neutrophils shown in Table 1.
In addition to the above reactions, we assume that the presence of bacteria in the res-
piratory tract recruits activated neutrophils; however, the recruitment rate saturates with
NA +B
ξ→ NA B is destroyed at rate ξ when it interacts with NA.
NA → NA experiences natural death.
∗ p→ B B is inhaled into lower respiratory tract at rate p.
Table 1: A summary of the interactions between B and NA
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the increase of bacteria. For this reason, we represent the recruitment rate of activated
neutrophils with a Michaelis-Menten-like term, B
1+sB
, where 1
s
is the amount of bacteria for
which the recruitment rate reaches its maximum level.
Further, we assume that the bacteria undergo logistic growth, which we represent with
the term kpgB(1 − B), where kpg is the bacterial growth rate. We represent the removal
of bacteria from the respiratory tract via the mucociliary escalator with the term − µ1B
µ2+B
.
A saturation term is appropriate since the rate at which this mechanism removes bacteria
levels off when the amount of bacteria is above a certain threshold.
These assumptions and the reactions in Table 1 yield the system of equations (3.1) and
(3.2).
dB
dt
=
(
p+ kpgB(1−B)− µ1B
µ2 +B
− ξBNA
)
B (3.1)
dNA
dt
=
(
−NA + B
1 + sB
)
NA (3.2)
The variables B and NA are dimensionless because the correct quantities for the bacteria
and neutrophils in the system is unknown. We include the parameters B and NA for
dimensional correctness. For the time being, we will set B = 1 and NA = 1. We will choose
parameters so that all relevant equilibria of System (3.1) - (3.2) are in the first quadrant
of the B-NA plane since negative quantities of bacteria and neutrophils are not possible.
In order for the system to be representative of biological phenomena, System (3.1) - (3.2)
must exhibit bistability between health and chronic infection for some set of parameters.
We define health as the state for which bacteria levels and neutrophil levels are low and
at equilibrium. Chronic infection is the state for which bacteria and neutrophil levels are
high and at equilibrium. We will first find parameters such that System (3.1) - (3.2) has
three equilibria in the first quadrant of the B-NA plane and then verify that the two outer
equilibria are stable, while the middle equilibrium is a saddle point. This will yield the
desired bistability.
The equilibria of System (3.1) and (3.2) are located at the intersections of the system’s
nullclines. We find the nullclines by setting each equation equal to zero and solving for the
variable NA in terms of B. For Equation (3.1), we have
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dB
dt
= 0⇒p+ kpgB(1−B)− µ1B
µ2 +B
− ξBNA = 0 (3.3)
⇒NA = −kpgB
3 + kpg(1− µ2)B2 + (p− µ1 + kpgµ2)B + pµ2
ξB(B + µ2)
. (3.4)
Similarly, for Equation (3.2), we obtain
dNA
dt
= 0⇒−NA + B
1 + sB
= 0 (3.5)
⇒NA = B
1 + sB
. (3.6)
Thus the two nullclines of System (3.1) and (3.2) are
N1A(B) =
−kpgB3 + kpg(1− µ2)B2 + (p− µ1 + kpgµ2)B + pµ2
ξB(B + µ2)
(3.7)
N2A(B) =
B
1 + sB
(3.8)
To find the equilibria of the System (3.1) and (3.2), we need to identify the points
(B∗, N∗A) at which the nullclines (3.7) and (3.8) intersect. The values B
∗ at which the two
nullclines intersect are found by finding the values of B such that
−kpgB3 + kpg(1− µ2)B2 + (p− µ1 + kpgµ2)B + pµ2
ξB(B + µ2)
− B
1 + sB
= 0 , or
f(B) = 0, g(B) 6= 0
where
f(B) =(−kpgs)B4 + (kpg − kpgs+ kpgsµ2 + ξ)B3 (3.9)
+ (kpg + ps− sµ1 − kpgµ2 + kpgsµ2 − µ2ξ)B2
+ (p− µ1 + kpgµ2 + psµ2)B + pµ2, and
g(B) =ξB(1 + sB)(µ2 +B) (3.10)
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p = 0.0012 kpg = 0.05 µ1 = 0.01
µ2 = 0.1 s = 5 ξ = 0.1
Table 2: For these parameter values, System (3.1) - (3.2) exhibits bistability. Bistability
in the model is necessary because the immune system can exhibit both health and chronic
inflammation.
We choose s = 5 so that the half-maximum value of the saturation term B
1+sB
occurs for
B = 0.2. We select values for the remaining parameters so that bistability is possible. We
also want the values of B and NA at the state of health to be very small and positive, while
the state of chronic infection should yield values of B and NA that are significantly higher
than those for the health state. The parameter values in Table 2 satisfy these qualities. The
four equilibria of the B-NA subsystem for the parameter values in Table 2 are displayed in
Table 3. (B3, NA3) has a negative B-coordinate, so we will not consider this equilibrium in
our analysis. The nullclines of System (3.1) - (3.2) and the remaining three equilibria can
be seen in Figure 2, which was generated with XPPAUT [3]. The code can be found in the
Appendix, Section A.1.
(B1, NA1) = (0.0580, 0.0450)
(B2, NA2) = (0.0902, 0.0621)
(B3, NA3) = (−0.2363, 1.3009)
(B4, NA4) = (0.3881, 0.1320)
Table 3: The equilibria of System (3.1) - (3.2) for the parameter values in Table 2.
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Figure 2: The nullclines of System (3.1) - (3.2). The blue nullcline shows where dB
dt
= 0, and
the red nullcline shows where dNA
dt
= 0. From left to right, the intersections of the blue and
red lines are the equilibria (B1, NA1), (B2, NA2), and (B4, NA4).
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Equilibrium Eigenvalue 1 Eigenvalue 2 Equilibrium Type
(B1, NA1) -0.996501 -0.003829 Stable Node
(B2, NA2) -0.995730 0.002854 Saddle Point
(B4, NA4) -0.995466 -0.010759 Stable Node
Table 4: The coordinates, eigenvalues, and description of the stability for each equilibrium
of the B-NA subsystem.
Now we will check the stability of the three equilibria (B1, NA1), (B2, NA2), and (B4, NA4).
Let f1(B,NA) be the right side of Equation (3.1), and let f2(B,NA) be the right side of
Equation (3.2). The linearization of System (3.1) - (3.2) is represented by the matrix J in
Equation (3.11).
J(B,NA) =
 ∂f1(B,NA)∂NA ∂f1(B,NA)∂B
∂f2(B,NA)
∂NA
∂f2(B,NA)
∂B
 =
 −1 1(1+sB)2
−ξB kpg(1− 2B)− µ1µ2(µ2+B)2 − ξNA
 (3.11)
The eigenvalues of this system, λ1, λ2 satisfy
det(J − λI2x2) = 0 (3.12)
⇒λ2 + λ
(
1− kpg(1− 2B) + µ1µ2
(µ2 +B)2
+ ξNA
)
− (3.13)
kpg(1− 2B) + µ1µ2
(µ2 +B)2
+ ξNA +
ξB
(1 + sB)2
= 0, (3.14)
where I2x2 is the identity matrix with two rows and two columns. The eigenvalues of
System (3.1) - (3.2) at the first-quadrant equilibria are summarized in Table 4. As desired,
the choice of parameters in Table 2 gives us a subsystem with one saddle point in between
two stable equilibria. This yields the desired bistability of the model.
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3.2 THE EFFECT OF PARAMETER ξ ON THE BISTABILITY OF THE
B-NA SUBSYSTEM
Before introducing IL-10 and the possibility of neutrophil paralysis into our model, we will
observe the effect of varying the parameter ξ on the bistability of the B-NA Subsystem,
given by Equations (3.1) and (3.2). The parameter ξ represents the rate at which activated
neutrophils are able to clear bacteria with which they come into contact. For the bifurcation
diagram of B versus ξ shown in Figure 3, we see that for low values of ξ, the amount
of bacteria remains at a high level and cannot return to a lower level, regardless of the
initial conditions. The upper branch in the bifurcation diagram represents a state of chronic
infection. If ξ increases past ξ = 0.09294, a lower and middle branch appear. The points on
the unstable portion of the lower branch are unstable spirals, and the points on the middle
branch are saddle points.
When ξ increases past ξ = 0.09759, a subcritical Andronov-Hopf bifurcation occurs,
transforming the equilibria on the bottom branch from unstable spirals to stable spirals.
When ξ ∈ (0.09759, 0.1182), it is possible for B to go to the chronic state or the lower
state of health. When ξ increases past ξ = 0.1182, a subcritical Andronov-Hopf bifurcation
occurs, transforming points on the top branch from stable spirals to unstable spirals. For
ξ ∈ (0.1182, 0.1267), the bacteria level could settle at the health state since all other equilibria
are unstable, or the system could produce oscillations. For ξ > 0.1267, the health state is
the only equilibrium in the system.
We see that by varying ξ, we can alter the bistability of System (3.1) - (3.2). A decrease
in ξ represents an immune system that is less effective at ridding the lower respiratory tract
of bacteria; it makes sense that lowering ξ leads to an immune system that can only exist
at a state of chronic infection and inflammation. In the next section, we introduce IL-
10 and neutrophil paralysis to the system. The increase in IL-10 from the IAV infection
causes the quantity of activated neutrophils to decrease, which has a similar effect on the
immune system as decreasing the value of ξ in the B-NA system; both changes represent
a weakening in the immune system’s ability to fight off bacterial infection and return to a
healthy equilibrium.
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Figure 3: The Bifurcation diagram of B versus ξ for the parameter values given in Table 2.
There is a parameter regime of ξ for which both health and chronic states exist and are stable.
Outside of this regime, the system must stay at either health or chronic infection. On the
upper and lower branch, stability changes through subcritical Andronov-Hopf bifurcations.
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3.3 THE ADDITION OF THE EFFECTS OF IL-10
Now we will consider the effects of anti-inflammatory mediators, specifically IL-10, on the
interaction between bacteria and activated neutrophils. As mentioned in Section 2.2.3, IL-10
has been observed to cause the inhibition of neutrophil migration to the site of infection. In
our model, NP refers to a neutrophil that has been inhibited from migrating to the site of
infection by IL-10. NA refers to a neutrophil that is able to migrate to the site of infection,
where it fights off the bacteria and produces IL-10. Although there are theories as to the
mechanisms of neutrophil paralysis, it is not known what all contributes to this phenomenon
[1]. For this reason, we simplify the process of neutrophil paralysis by describing it in terms
of interactions between neutrophils and IL-10.
We assume that an interaction between IL-10 and an activated neutrophil prevents the
neutrophil from getting to the site of infection; the activated neutrophil becomes a paralyzed
neutrophil. Since the IL-10 produced in response to the bacterial infection, as well as that
produced from the IAV infection, will trigger neutrophil paralysis, we include effects from
both sources of IL-10 in the neutrophil paralysis reaction. From the data point in Figure 1
plotted at t = 0 , we know that the level of IL-10 pre-IAV infection is 80.46 pg/mL. The
function IIAV is the difference between the piecewise-linear interpolation of the first seven
IL-10 data points seen in Figure 1 and 80.46, i.e. IIAV is the additional IL-10 produced
by the pro-inflammatory wave in response to the IAV infection. We assume also that the
neutrophil paralysis is temporary and that the affected neutrophil will return to an active
state before natural death. IL-10 is also assumed to eventually decay. Since IIAV is the
excess IL-10 above the healthy steady state caused by IAV infection, IIAV (t) = 0 outside of
the time during which the influenza infection takes place, meaning that we do not need to
account for its decay. Table 5 summarizes these reactions.
Since the pro-inflammatory wave initiates the anti-inflammatory wave of the immune re-
sponse, we represent the recruitment of IL-10 by activated neutrophils to the site of infection
with the term ζ1NA
1+ζ2(I+IIAV (t))
. This term is appropriate since an abundance of IL-10 at the
site of infection causes IL-10 production to saturate for a fixed level of activated neutrophils.
The model resulting from the above assumptions and the reactions in Tables 1 and 5 is given
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NA + I
γ→ NP + I NA is turned into NP at rate γ when it interacts with I.
NA + IIAV
γ→ NP + IIAV NA is turned into NP at rate γ when it interacts with IIAV .
NP → NA NP will turn back into NA.
I
η→ I decays at rate η.
Table 5: The interactions among NA, NP , and I
by System (3.15) - (3.18)
dNP
dt
= (γ(I + IIAV (t))NA −NP ) NP (3.15)
dNA
dt
=
(
−NA + B
1 + sB
)
NA − (γ(I + IIAV (t))NA −NP ) NP (3.16)
dB
dt
=
(
p+ kpgB(1−B)− µ1B
µ2 +B
− ξBNA
)
B (3.17)
dI
dt
=
(
ζ1NA
1 + ζ2(I + IIAV (t))
− ηI
)
I (3.18)
The parameters NP , NA , B, and I are time-scaling parameters included in order to
obtain system dynamics as close to scientific observation as possible.
In order to choose the remaining parameters, we must make more assumptions while
taking into account what we know to be true from experimental observation. Since health
must be a possible steady state of System (3.15) - (3.18),
dNP
dt
= 0 (3.19)
IIAV (t) ≡ 0 during health ⇒ (γINA −NP ) NP = 0 (3.20)
⇒ γINA −NP = 0 (3.21)
⇒ γ = NP
INA
. (3.22)
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We will assume that the level of activated neutrophils is equal to the level of paralyzed
neutrophils during the state of health. From this assumption and the fact that the level of
IL-10 at the healthy state is I(0) = 80.46, we have that γ = 1
80.46
≈ 0.01243. We will choose
ζ2 = 0.001; since ζ2 is multiplied by I, which takes on values much larger than those of NA,
making ζ2 too large will cause the term
ζ1NA
1+ζ2I
to have little effect on the dynamics of I.
The motivation for the development of System (3.15) - (3.18) is to obtain a model sup-
porting the hypothesis that the second hill in the IL-10 data in Figure 1 results from sec-
ondary bacterial infection in the host and that this secondary bacterial infection occurs as a
result of immune dynamics triggered by the primary IAV infection.
We choose the parameters for System (3.15) - (3.18) with the following considerations in
mind:
1. The bacteria most often responsible for bacterial pneumonia is S. pneumoinae [2], [5], [8].
S. pneumoniae reproduces through binary fission, doubling once every 20 to 30 minutes
[12]. If we take the doubling time to be 30 minutes or 1
48
days, we can solve the following
differential equation to determine a value of B.
dB
dt
= BkpgB (3.23)
⇒B(t) = B0exp(Bkpgt) (3.24)
⇒2B0 = B
(
1
48
)
= B0exp
(
Bkpg
48
)
(3.25)
⇒Bkpg = 48 ln(2) ≈ 33.27 (3.26)
Since kpg = 0.05, a result obtained in Section 3.1, we set B = 665.4.
2. S. pneumoniae infection occurs in the lungs one to seven days after viral infection of the
upper respiratory tract [2]. We choose the time-scaling parameters NA and NP so that
the bacterial infection matches this observation.
3. System (3.15) - (3.18) cannot be insensitive to the increase in IL-10 caused by the IAV
infection; the dynamics of the system must be responsive to the presence of IIAV .
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4. The solution of System (3.15) - (3.18) should stay near the healthy equilibrium in the
absence of the IAV infection. We choose parameters η and I so that the system demon-
strates these last two qualities. When finding the healthy equilibrium state, which will
also serve as our set of initial conditions, we must keep the following in mind with respect
to the state of health:
a. IIAV ≡ 0, since IIAV is nonzero only in the first 9 days of IAV infection.
b. I ≡ 80.46 pg/mL, since this is the amount of IL-10 shown in the IAV IL-10 data
before IAV infection and since we assume that the mice are initially healthy.
c. When we let ξ = 0.165 in System (3.1) - (3.2) and let all other parameters in the
subsystem remain as they are in Table 2, the steady state values of B and NA will
be the same for both systems. Indeed, when System (3.15) - (3.18) is at equilibrium,
dNP
dt
= 0 (3.27)
⇒ γ(I + IIAV )NA −NP = 0 (3.28)
Thus
dNA
dt
=
(
−NA + B
1 + sB
)
NA − (γ(I + IIAV )NA −NP ) NP = 0 (3.29)
⇒ dNA
dt
=
(
−NA + B
1 + sB
)
NA = 0 (3.30)
This means that in System (3.15) - (3.18), NA behaves as it does in the Subsystem
(3.1) - (3.2). Since the dynamics of B in System (3.15) - (3.18) do not depend on
any variables besides NA, we have that the equilibrium values of B and NA in the
larger system should be the same as they are in the B-NA Subsystem.
d. For Equations (3.20) - (3.22), we assume that NA ≡ NP at health.
The parameter values and initial conditions for System (3.15) - (3.18) are shown in Tables
6 and 7, respectively. Although these parameter values were selected by hand, a closer fit
to the IAV IL-10 data could be obtained with the use of more sophisticated parameter
estimation techniques.
Figures 4 and 5 are simulations of System (3.15) - (3.18) with the parameter values in
Table 6. These simulations were run using XPPAUT and the code in the Appendix, Section
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p = 0.0012 kpg = 0.05 µ1 = 0.01 µ2 = 0.1
s = 5 ξ = 0.165 γ = 0.01243 ζ2 = 0.001
η = 0.97 NP = 0.15 NA = 0.27 B = 665.4
ζ1 = 2384.48 I = 5
Table 6: Along with the initial conditions in Table 7, these parameter values for System
(3.15) - (3.18) provide dynamics similar to those observed in the IL-10 data from Figure 1.
B(0) = 0.0429609
NA(0) = 0.03536446
NP (0) = 0.03536863
I(0) = 80.46
Table 7: For the parameter values in Table 6, these initial conditions for System (3.15) -
(3.18) provide dynamics similar to those observed in the IL-10 data from Figure 1.
23
A.2. For this set of parameter values, the system yields dynamics for Itot = I + IIAV that
closely match the IL-10 data in Figure 1. Indeed, we see from Figure 4 that the dynamics
of Itot experience a large peak followed by a smaller, secondary peak. The first peak in Itot
is mostly driven by IIAV ; however, the dynamics occurring after the first peak are a result
of the dynamics of System (3.15) - (3.18). In Figure 4, we compare Itot with the IL-10 IAV
data and observe the addition of I and IIAV to form Itot.
In Figure 5, we see that the bacterial level peaks between Day 6 and Day 7 post-IAV
infection. We also observe that the level of activated neutrophils decreases between Day
2 and Day 7, while the level of paralyzed neutrophils increases during this time. These
behaviors occur at the same time as the first, larger increase in IL-10 shown in Figure 1.
Recall that when IL-10 levels increase, activated neutrophils are inhibited from migrating
to the site of infection, allowing for bacteria at the site of infection to populate without
hindrance by the activated neutrophils. The way in which IIAV varies within the first 9
days post-IAV infection has the same effect on System (3.15) - (3.18) as decreasing and then
increasing ξ in the Subsystem (3.1) - (3.2). In the absence of IIAV , the system remains at
the steady state of health, which shows that the system is reacting to the change in IL-10
resulting from the primary IAV infection.
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Figure 4: The dynamics of Itot from System (3.15) - (3.18) closely predict the IL-10 data
post IAV infection. Itot is the sum of the IL-10 recruited by the bacterial infection, I, and
the excess IL-10 recruited by the IAV infection, IAV .
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Figure 5: The dynamics of B, NA, and NP from System (3.15) - (3.18) demonstrates timing
similar to that observed experimentally.
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4.0 MODEL 2: STOCHASTIC INHALATION OF BACTERIA
4.1 DEVELOPMENT OF MODEL 2
We have developed a model for an immune system with output that is qualitatively realistic
and produces IL-10 levels similar to the data collected by Toapanta et al. For this model, the
rate of inhalation of bacteria into the lower respiratory tract is represented by a constant;
however, the flow of bacteria into the lower respiratory tract is not constant. Instead, small
quantities of bacteria are inhaled many times per day. In this next model, we assume that the
same amount of bacteria is inhaled for every inhalation of bacteria and that the inhalation
of bacteria is a Poisson process. With this change, we have the model represented by the
System (4.1) - (4.4).
dNP
dt
= (γ(I + IIAV (t))NA −NP ) NP (4.1)
dNA
dt
=
(
−NA + B
1 + sB
)
NA − (γ(I + IIAV (t))NA −NP ) NP (4.2)
dB
dt
=
(
kpgB(1−B)− µ1B
µ2 +B
− ξBNA
)
B + p1(t) (4.3)
dI
dt
=
(
ζ1NA
1 + ζ2(I + IIAV (t))
− ηI
)
I (4.4)
p1(t) = b1
n∑
i=1
δ(t− τi),
where δ is the Dirac delta function given by
δ(s) = lim
a→0
1
2a
exp
(
−
∣∣∣s
a
∣∣∣)
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The waiting times {τi+1−τi} between inhalations of bacteria are exponentially distributed
with rate parameter λ. The parameter b1 represents the amount of bacteria inhaled at each
time τi. Some of the values for the parameters in System (4.1) - (4.4) can be taken from
our work with System (3.15) - (3.18). However, the parameters involving the stochasticity
of the bacterial inhalation; such as λ and p1; as well as some of the parameters representing
immune system characteristics; such as ξ, ζ1, η, and γ; must be set. Our first step in doing
so is to consider that the average influx of bacteria in the stochastic system should be the
same as the influx of bacteria in the deterministic system, i.e. pˆ1 in System (4.1) - (4.4)
should equal Bp in System (3.15) - (3.18).
Note that the expected value of the function p1(t) over a given time interval [0, T ] is
pˆ1 =
b1 〈n〉 (T )
T
,
where 〈n〉 (T ) is the expected number of times that p1(t) is nonzero for t ∈ [0, T ]. Since the
number of times for which p1(t) 6= 0 is a Poisson process,
〈n〉 (T ) =
∫ T
0
λdt = λT (4.5)
⇒ pˆ1 = b1λT
T
= b1λ (4.6)
Since we assume pˆ1 = Bp, we obtain that
Bp = b1λ⇒ b1 = Bp
λ
=
0.0012(665.4)
λ
=
0.79848
λ
We will assume that the values of parameters B, NA , NP , I , s, kpg, µ1, µ2, and ζ2 are
the same as in Table 6. We will find new values for the parameters λ, ζ1, η, γ, and ξ for the
stochastic model such that we observe the following behaviors:
1. In the absence of IL-10 from IAV infection, the IL-10 level in the model remains around
the baseline level of 80.46 pg/mL and does not jump spontaneously.
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2. In an experiment by W. J. Doyle in which humans were experimentally infected with
influenza, 15% of the subjects were found to be nasopharyngeally infected with S. pneu-
moniae 6 days post viral challenge [2]. We will attempt to find parameters so that there
is a 0.15 probability of a bacterial infection, by which we mean a jump in the bacteria
level from the baseline level of 0.04 cfu to at least 0.2 cfu.
3. The average of the IL-10 trajectories and the IAV IL-10 data agree at most if not all of
the IAV IL-10 data points.
Each of the IL-10 data points shown in Figure 1 is an average of IL-10 counts from six
mice, all of which had to be euthanized in order to obtain these results. This means that the
data collected by Toapanta et al. represents an average of immune system dynamics, across
different immune systems. We assume that the mice in the experiment had identical immune
systems, and observe whether or not System (4.1) - (4.4) exhibits the three behaviors listed
above at a given parameter point by running the simulation 100 times and averaging the
solutions. In order to find numerical solutions of this system, we used XPPAUT with the
code found in Appendix A.3.
Although Behaviors 1 and 2 are important in finding a good parameter fit for System (4.1)
- (4.4), Behavior 3 represents the primary goal of Section 4 - to develop a model supporting
the hypothesis that bacterial superinfection is responsible for the small, secondary hump in
the IAV IL-10 data. (See Figure 1.) To check that the system exhibits Behavior 3 at a given
parameter point, we find the average of the solutions Itot = IIAV + I and compare it to the
IAV IL-10 data.
Figure 6 shows the results of five consecutive simulations of System (4.1) - (4.4) at the
parameter values specified in Table 8. It is clear from the figure that the steady state level
for I for these parameter values is close to 96 as opposed to being near 80.46, so System
(4.1) - (4.4) does not completely satisfy Behavior 1 at the given parameter point, although
the chance of a spontaneous bacterial infection is very low. Furthermore, for this parameter
point, the probability that bacterial infection occurs is 0.52, so System (4.1) - (4.4) also does
not satisfy Behavior 2 at the given parameter point.
However, System (4.1) - (4.4) does satisfy Behavior 3. In Figure 7, the average of Itot
over 100 trials is compared to the IAV IL-10 data. From this plot, we see that Itot matches
29
B = 665.4 NP = 0.15 s = 5 NA = 0.27
I = 15 kpg = 0.05 µ1 = 0.01 µ2 = 0.1
ζ2 = 0.001 b1 =
Bp
λ
λ = 600 ζ1 = 2305
ξ = 0.161 η = 0.78 γ = 0.0048
Table 8: The parameter values for System (4.1) - (4.4) that yield the results seen in Figures
6, 7, and 8.
the trend established by the IAV IL-10 data points. In Figure 8, we see the average dynamics
of bacteria, activated neutrophils, and paralyzed neutrophils corresponding to the 100 trials
from which the average Itot in Figure 7 was found. We see that that the bacteria does
not peak as high as it does for System (3.15) - (3.18) in Figure 5, but this makes sense
because these are dynamics over trials for which bacterial infection did or did not occur. For
example, Figure 9 shows the dynamics of B, NA, and NP for a trial for which there was
bacterial infection, while Figure 10 shows the solutions to the same variables for a trial for
which no bacterial infection occurred.
This model with stochastic bacteria inhalation is more realistic than the model with
constant rate of bacterial inhalation because it demonstrates the possibility of bacterial
infection occurring with an assigned probability. In System (3.15) - (3.18), the parameter
values determine fully whether or not the immune system will be able to contain the bacteria
before infection can occur, but we know from experience that hosts with healthy immune
systems do not obtain lower-respiratory tract infections never or always; there is some chance
of getting sick, but there is no certainty of contracting a bacterial infection or not.
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Figure 6: The dynamics of I for five different trials of System (4.1) - (4.4).
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Figure 7: The average over 100 trials of Itot from System (4.1) - (4.4) and the IAV IL-10
data.
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Figure 8: The dynamics of B, NA, and NP from System (4.1) - (4.4). The maximum average
bacteria level is lower than the maximum bacteria level obtained from the parameter selection
for System (3.15) - (3.18). (See Figure 5.)
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Figure 9: The dynamics of B, NA, and NP from System (4.1) - (4.4) for a trial during which
bacterial infection occurred.
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Figure 10: The dynamics of B, NA, and NP from System (4.1) - (4.4) for a trial during
which bacterial infection did not occur.
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4.2 CONTRIBUTING FACTORS TO BACTERIAL INFECTION IN
MODEL 2 SOLUTION
Notice from Figure 6 that the solution to System (4.1) - (4.4) will fall under two distinct
cases, one of which results in bacterial infection, and one of which does not. We wish to
determine the factors that contribute to whether or not the solution results in bacterial
infection. After observing many simulations System (4.1) - (4.4), one observes that when
bacterial infection does occur in the solution, it occurs within the approximate time window
between Day 4 and Day 8. Figure 11 shows a plot of B(t) for four simulations of the System,
one of which does not result in bacterial infection and three of which do, and Figure 12 shows
the mean B(t) among cases of bacterial infection and the mean B(t) among cases of health.
The dependence on the occurrence of bacterial infection on the time window of Day 4
to Day 8 suggests that there is some aspect of the System that makes a sudden jump in
bacteria levels possible during this time period and highly improbably outside of the time
period. In Figure 13, we see a plot of IIAV (t), the excess IL-10 produced in response to
the IAV infection. During the time window from Day 4 to Day 8, IIAV (t) ≈ 200 or greater.
However, IIAV (t) ≈ 200 does not guarantee that the solution to the System exhibits bacterial
infection since it is possible for the System to remain at health despite the temporary increase
in levels of IIAV (t).
We wish to examine the effect of IIAV (t) on System (4.1) - (4.4). To do so, we make
some assumptions in order to reduce the deterministic model, System (3.15) - (3.18), to a
one-dimensional ODE. Since we would like to compare the results of this analysis to the
stochastic model with the parameters in Table 8, we will consider the deterministic model
with the parameter values in Table 8 relevant to System (3.15) - (3.18).
First, we replace IIAV (t) with a constant parameter called IAV so that we can explicitly
observe the effects of different values of IIAV (t) on the occurrence of bacterial infection. This
yields the system of differential equations, System (4.7) - (4.10).
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Figure 11: Four simulations of System (4.1) - (4.4). The three simulations that do result in
bacterial infection are representative of most other simulations of the System that result in
infection in that bacterial infection does not occur outside of an approximate time window
from Day 4 to Day 8. (See Figure 12 for the mean of B(t) from 30 simulations for which
bacterial infection occurred.) From Figure 13, we see IIAV (t) ≈ 200 or greater in this time
window.
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Figure 12: The mean of B(t) from 30 simulations of System (4.1) - (4.4) for which bacterial
infection does occur and the mean over 30 simulations for which bacterial infection does not
occur.
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Figure 13: A plot of IIAV (t), the additional IL-10 produced as a result of the IAV infection.
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dNP
dt
= (γ(I + IAV )NA −NP ) NP (4.7)
dNA
dt
=
(
−NA + B
1 + sB
)
NA − (γ(I + IAV )NA −NP ) NP (4.8)
dB
dt
=
(
p+ kpgB(1−B)− µ1B
µ2 +B
− ξBNA
)
B (4.9)
dI
dt
=
(
ζ1NA
1 + ζ2(I + IAV )
− ηI
)
I (4.10)
As we change the values of parameter IAV , we observe that I ∈ [72.92, 96.16] for System
(4.7) - (4.10); we let I ≡ 96.16, the steady state value at health I(0), since the extent to which
I changes is small compared to the extent to which IAV changes. I ≡ 96.16 means that
the parameter IAV must take on values in the interval [0, 372.48] because Itot = IIAV (t) + I
must take on values in [0, 468.46]. Also, note that Ntot(0) = NA(0) + NP (0) = 0.052 and
that Ntot ∈ [0.052, 0.111]; we let Ntot ≡ 0.052. Observe the following.
0 =
dNP
dt
= (γ((IAV )NA −NP )) NA (4.11)
⇒ NP = γ(IAV )NA (4.12)
This yields
Ntot = NA +NP (4.13)
⇒ Ntot = NA + γ(IAV )NA (4.14)
⇒ NA = Ntot
1 + γ(IAV )
(4.15)
Plugging this value of NA into
dB
dt
, we obtain
dB
dt
=
(
p+ kpgB(1−B)− µ1B
µ2 +B
− ξNtotB
1 + γ(IAV )
)
B (4.16)
We set dB
dt
= 0 and solve for B at several different values of IAV to observe how changes in
IAV affect the steady state values of B. Figure 14 shows plots of the equation for several
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values of IAV . For IAV = 0, we see that there are three equilibria - one unstable equilibrium
between two stable equilibria. As IAV increases, the unstable equilibrium and the stable
equilibrium to its left disappear. Figure 15 provides a closer look at this phenomenon. When
IAV is below a certain value, B must be at least 0.06, or larger depending on how small
IAV is, in order for it to be pulled toward the higher stable equilibrium. Otherwise, B is
pulled toward the lower stable equilibrium. The value that B must be in order for it to be
pulled toward the higher stable equilibrium decreases as IAV increases.
We can apply these findings to the stochastic system. From what we observed above,
B must be above a necessary value dependent on the value of IIAV (t) in order for bacterial
infection to occur. However, due to the constraints on the stochasticity of B influenced by
the values of parameters b1 and λ in System (4.1) - (4.4), the lower the value of IIAV (t), the
more improbable is is that B will reach the necessary value needed in order to be attracted
to the higher equilibrium. In other words, whether or not the solution of System (4.1) -
(4.4) results in bacterial infection at a certain time t∗ depends on the value of IIAV (t∗) and
whether or not the stochasticity of the system has brought B(t∗) to a large enough value so
as to be pulled toward the higher equilibrium of infection.
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Figure 14: A plot of dB
dt
, Equation (4.16), versus B for several values of IAV . The value of
IAV determines the number of equilibria of Equation (4.16). See Figure 15 for a closer look
at the disappearance of the left and middle equilibria as IAV increases.
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Figure 15: The left and middle equilibria of Equation (4.16) disappear as IAV increases.
When IAV < 100, B must stochastically jump higher than the middle equilibrium in order
to be pulled toward the stable equilibrium to the right. (See Figure 14.) For this reason,
bacterial infection is highly unlikely to occur for IAV < 100.
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5.0 CONCLUSION
Through the above research, we were able to develop a simple model of bacterial infection
involving bacteria, neutrophils, and IL-10. We used this model to support the possibility
that the unexpected secondary hump in the IAV IL-10 data collected by Toapanta et al. is
due to an unintended bacterial superinfection occurring after the mice were inoculated with
IAV. While we were able to find parameters for the deterministic model that satisfied all
of our criterion and yielded results that matched the IL-10 data, the model with stochastic
bacterial inhalation produced a more realistic infection scenario by modeling the somewhat
random nature of illness and infection. In order to choose parameters that yield results
exhibiting all expected behaviors, we could perform a sensitivity analysis on the parameters
to find out which are worth varying and which are not in order to obtain the desired results.
One reason for the difficulty in fitting System (4.1) - (4.4) is that we are working with one
specific immune system as established by our parameter point choice. It is probable that,
since the IAV IL-10 data comes from many different rats, we would want to be able to vary
the parameters slightly in order to obtain a wider spread of the possible immune responses.
For example, for the parameter choice in Table 8, all solutions return to the healthy state
state, but perhaps some of the mice were not able to recover from the bacterial infection.
In this case, we would want the variation in parameters to be such that the change in IL-10
caused by the IAV infection can cause bacteria levels to jump to the high branch in Figure 3,
while also being able to allow bacteria levels to stay at the lower branch. In order to obtain
this, we could include stochastic variation of the parameters in a modification of System (4.1)
- (4.4). We could also vary the parameter b1 stochastically, since the host probably inhales
varying amounts of bacteria as opposed to inhaling the same amount of bacteria every time
bacteria is taken into the lower respiratory tract.
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Finally, these models could be useful in considering the probability of contracting sec-
ondary bacterial pneumonia after an IAV infection with respect to individuals with com-
promised immune systems and the elderly. Community acquired pneumonia is a common
complication for the elderly living in nursing homes or for chronically ill patients who spend
much time in hospital intensive care units.
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APPENDIX
CODE
A.1 NAB PP.ODE CODE
NA’=-NA+B/(1+ss*B)
B’=p+kpg*B*(1-B)-(m1*B/(m2+B))-xi*B*NA)
par p=0.0012, kpg=0.05, m1=0.01, m2=0.1, xi=0.1, ss=5
init NA=0.0449829
init B=0.0580362
@ method=rk4, tol=1e-7, dt=0.01, total=200, bounds=1e70
@ maxstore=100000
done
A.2 NB V3 C.ODE CODE
#Note: IL10_linear.tab is the IL-10 data minus baseline value of 80.64
table ca_ IL10_linear.tab
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table caFull_ IL10_extended.tab
ca(t)=if((t<=9.0949)&(t>=0))then(ca_(qq*(t)))else(0.0)
caFull(t)=if((t<=19)&(t>=0))then(caFull_(t))else(if(t<0)then(80.46)else(113.28))
NP’=(g*K*NA-NP)*epsNp
NA’=(-NA+B/(1+ss*B))*epsNa-(g*K*NA-NP)*epsNp
B’=(p+kpg*B*(1-B)-(m1*B/(m2+B))-xi*B*NA)*epsB
K’=(ca(t)+z1*NA/(1+z2*K)-y*K)*epsK
par qq=1, epsNp=0.15, epsK=15, z1=2384.48, z2=0.001
par g=0.01243, epsNA=0.27, ss=5, y=0.97
par epsB=665.4, p=0.0012, kpg=0.05, m1=0.01, m2=0.1, xi=0.165
aux myca=ca(t)/1000
aux IL10=caFull(t)
init NP=0.03536446
init NA=0.03536446
init B= 0.0429609
init K=80.46
@ method=rk4, tol=1e-7, dt=0.01, total=60, bounds=1e70
@ maxstore=100000
done
A.3 NB V5 2.ODE CODE
#Note: IL10_linear.tab is the IL-10 data minus baseline value of 80.64
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table ca_ IL10_linear.tab
table caFull_ IL10_extended.tab
ca(t)=if((t<=9.0949)&(t>=0))then(ca_(qq*(t)))else(0.0)
caFull(t)=if((t<=19)&(t>=0))then(caFull_(t))else(if(t<0)then(80.46)else(113.28))
NP’=(g*(K+ca(t))*NA-NP)*epsNp
NA’=(-NA+B/(1+ss*B))*epsNa-(g*(K+ca(t))*NA-NP)*epsNp
B’=(p+kpg*B*(1-B)-(m1*B/(m2+B))-c*B*NA)*epsB
K’=(z1*NA/(1+z2*(K+ca(t)))-y*K)*epsK
nap’=(-nap+na)/tauf
switch’=0
switch2’=0
markov z 2
{0} {lambda}
{100000000000} {0}
global 1 z-.5 {b=b+b1}
trial’=0
par tauf=1
global 1 nap-thresh1 {switch2=switch2+1}
global -1 nap-thresh2 {switch2=switch2+1}
global 1 nap-thresh1 {switch=switch+(t>0)}
global -1 nap-thresh2 {switch=switch+(t>0)}
global 1 t-tend {out_put=1}
par thresh1=0.05, thresh2=0.045, thresh3=300, thresh4=90
par thresh5=0.5, thresh6=0.3
par lambda=600, p=0, c=0.161
par qq=1, epsNp=0.15, epsK=15, z1=2304.72, z2=0.001
par g=0.0048, epsNA=0.27, ss=5, y=0.78
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par epsB=665.4, kpg=0.05, m1=0.01, m2=0.1
par tend=60.01234
b1=0.79848/lambda
only trial,switch,switch2,bzero,xi
aux bzero=b1
aux xi=c
aux IL10=caFull(t)
aux I=K+ca(t)
init NP=0.01602396
init NA=0.03433738
init B=0.04145409
init K=80.46
init switch=0
@ method=euler, tol=1e-7, dt=0.001, total=91, bounds=1e70
@ maxstore=100000, njmp=5, T0=-30
@ trans=100
@ range=1,rangereset=np,rangestep=100,rangeover=trial
@ rangelow=0,rangehigh=100
done
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